# Repligen Corporation – Consensus ‘buy’ rating and 9.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-consensus-buy-rating-and-9.2-upside-potential-2/4121134701
- Published: 2023-11-30T12:40:26+00:00
- Author: Charlotte Edwards

**Repligen Corporation** which can be found using ticker (RGEN) now have 13 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between $210.00 and 
$148.00 and has a mean target at $171.38. Given that the stocks previous close was
at $156.90 this would indicate that there is a potential upside of 9.2%. Also worth
taking note is the 50 day moving average now sits at $149.68 and the 200 moving 
average now moves to $161.14. The company has a market cap of 8.90B. The current
share price for the company is: $159.49 USD

 The potential market cap would be $9,726,438,295 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 78.57, revenue per share of $12.04 and a 2.08% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on:
